[1]师帅,褚瑜光,宋庆桥,等.银丹心脑通软胶囊治疗高脂血症疗效及安全性系统评价[J].西部中医药,2019,32(05):44-50.
　SHI Shuai,CHU Yuguang,SONG Qingqiao,et al.Systematic Review of the Safety and Clinical Effects of YinDan XinNaoTong Soft Capsules in the Treatment for Hyperlipemia[J].Western Journal of Traditional Chinese Medicine,2019,32(05):44-50.
点击复制

银丹心脑通软胶囊治疗高脂血症疗效及安全性系统评价
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
32
期数:
2019年05期
页码:
44-50
栏目:
出版日期:
2019-05-15

文章信息/Info

Title:
Systematic Review of the Safety and Clinical Effects of YinDan XinNaoTong Soft Capsules in the Treatment for Hyperlipemia
文章编号:
1004-6852(2019)05-0044-07
作者:
师帅，褚瑜光，宋庆桥，杜柏，胡元会，石晶晶，薄荣强
中国中医科学院广安门医院，北京 100053
Author(s):
SHI Shuai, CHU Yuguang, SONG Qingqiao, DU Bai, HU Yuanhui, SHI Jingjing, BO Rongqiang
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
关键词:
高脂血症; 银丹心脑通软胶囊; 系统评价
Keywords:
hyperlipemia;  YinDan XinNaoTong soft capsules;  systematic review
分类号:
R568
摘要:
目的：系统评价银丹心脑通软胶囊治疗高脂血症的疗效和安全性。方法：计算机检索Cochrane图书馆、PubMed、Embase、Medline、CNKI、CBM、VIP、万方数据库等数据库，纳入相关RCT，并进行评价，采用Revman 5.3软件分析数据。结果：纳入22篇RCTs，共2 815例受试者。相比对照组，银丹心脑通软胶囊的血脂总疗效较高［OR=3.43，95%CI(2.38，4.95)，P＜0.00001］。治疗后总胆固醇(TC)水平低于对照组［WMD=-0.88，95%CI(-1.10，-0.66)，P＜0.00001］。治疗后甘油三酯(TG)水平低于对照组［WMD=-0.54，95%CI(-0.65，-0.43)，P＜0.00001］。治疗后高密度脂蛋白(HDL-C)高于对照组［MD=0.28，95%CI(0.20，0.35)，P＜0.00001］。治疗后低密度脂蛋白(LDL-C)水平低于对照组［MD=-0.48，95%CI(-0.59，-0.36)，P＜0.00001］。各组不良反应发生率差异有统计学意义［OR=0.51，95%CI(0.30，0.84)，P=0.009］。结论：银丹心脑通软胶囊治疗高脂血症疗效明显，对TG、TC、HDL-C、LDL-C改善有效，对不合并糖尿病亚组的TC及对合并糖尿病亚组的HDL-C疗效确切。不良反应发生率低于其他药物，推荐临床应用于高脂血症的治疗，并建议补充更多高质量的相关研究。
Abstract:
Objective: To assess the safety and clinical effects of YinDan XinNaoTong soft capsules in the treatment for hyperlipemia systematically. Methods: Computer was used to search Cochrane library, PubMed, Embase, Medline, CKNI, CBM, VIP, Wanfang and others, the related RCTs were included and assessed, the data was analyzed using Revman 5.3 software. Results: All 22 related RCTs were included, involving 2 815 patients. Compared with the control group, total clinical effects of blood lipid in the group of YinDan XinNaoTong soft capsules were higher ［OR=3.43, 95%CI(2.38, 4.95), P＜0.00001］. After treating, the level of TC was lower than the control group ［MD=-0.88, 95%CI(-1.10, -0.66), P＜0.00001］. After treating, the levels of TG were lower than the control group ［MD=-0.54, 95%CI(-0.65, -0.43), P＜0.00001］. After treating, the levels of HDL-C was higher than the control group［MD=-0.28, 95%CI(0.20, 0.35), P＜0.00001］. The levels of LDL-C was lower than the control group ［MD=-0.48, 95%CI(-0.59, -0.36), P＜0.00001］. There was no statistical meaning in the comparisons of the incidences of adverse reactions among different groups ［OR=0.51, 95%CI(0.30, 0.84), P=0.009］. Conclusion: YinDan XinNaoTong soft capsules are effective in the treatment for hyperlipemia, it could effectively improve the levels of TC, TG, HDL-C and LDL-C, and it could gain definite effects in improving TC of the patients who didn't suffer diabetes subgroup and HDL-C of the patients suffering diabetes subgroup. No adverse reaction happen, and it showed no obvious difference when it is compared with other drugs, it should be recommended in clinical application and the related studies in high quality should be supplemented.

相似文献/References:

[1]杨健,张红武△,杨如意.活血化浊胶囊治疗高脂血症的实验研究[J].西部中医药,2012,25(08):17.
　YANG Jian,ZHANG Hong-wu,YANG Ru-yi.Experimental Study on HuoXue HuaZhuo Capsule in Treating Hyperlipidemia[J].Western Journal of Traditional Chinese Medicine,2012,25(05):17.
[2]高艳琼,延华,金瑞瑞.泽泻汤治疗高脂血症的临床疗效观察[J].西部中医药,2015,28(09):88.
[3]高世东.从肝脾肾论治高脂血症[J].西部中医药,2013,26(06):18.
　GAO Shidong.On Hyperlipoidemia Treated from Liver, Spleen and Kidney[J].Western Journal of Traditional Chinese Medicine,2013,26(05):18.
[4]袁帆,张全华,冉子伯.降脂类中药组方治疗高脂血症临床观察[J].西部中医药,2014,27(05):85.
　YUAN Fan,ZHANG Quanhua,RAN Zibo.Clinical Observation on Lipid-lowering Herbs and Prescriptions in the Treatment for Hyperlipidemia[J].Western Journal of Traditional Chinese Medicine,2014,27(05):85.
[5]滕云.七味消脂饮治疗高脂血症临床观察[J].西部中医药,2013,26(05):77.
　TENG Yun.Clinical Observation on QiWei XiaoZhiYin in Treating Hyperlipoidemia[J].Western Journal of Traditional Chinese Medicine,2013,26(05):77.
[6]张和平,谈建新,王敬敏,等.心脑通配方对大鼠颈总动脉粥样硬化斑块中MMP-2的影响[J].西部中医药,2014,27(03):32.
　ZHANG Heping,TAN Jianxin,WANG Jingmin,et al.Effects of XinNaoTong Prescription on MMP-2 in Carotid Atherosclerotic Plaque of Rats[J].Western Journal of Traditional Chinese Medicine,2014,27(05):32.
[7]李龑,杨舒淳,吴芳,等.化脂丸对高脂血症患者血脂的影响*[J].西部中医药,2014,27(04):31.
　LI Yan,YANG Shuchun,WU Fang,et al.Effects of HuaZhi Pill on Blood Lipid of the Patients with Hyperlipemia[J].Western Journal of Traditional Chinese Medicine,2014,27(05):31.
[8]苏奋翔,张艳霞,安方玉,等.林氏降脂方对高脂血症大鼠血脂和血液流变学的影响[J].西部中医药,2015,28(10):12.
[9]苏奋翔,张艳霞,安方玉,等.林氏降脂方对高脂血症大鼠肾脏的影响[J].西部中医药,2016,29(04):22.
　SU Fenxiang,ZHANG Yanxia,AN Fangyu,et al.Effects of LinShiJiangZhi Prescription on the Kidney of the Rats with Hyperlipoidemia[J].Western Journal of Traditional Chinese Medicine,2016,29(05):22.
[10]李淑玲,刘凯△.李应东教授从脾气虚论治高脂血症[J].西部中医药,2017,30(03):53.
　LI Shuling,LIU Kai.Professor LI Yingdong′s Treatment for Hyperlipidemia from Spleen-Qi Deficiency[J].Western Journal of Traditional Chinese Medicine,2017,30(05):53.

备注/Memo

备注/Memo:
收稿日期：2018-10-12 作者简介：师帅(1991—)，男，在读博士研究生。研究方向：心血管疾病的中医药防治。
更新日期/Last Update: 2019-05-15